Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Metabolomics of Small Intestine Neuroendocrine Tumors and Related Hepatic Metastases.

Imperiale A, Poncet G, Addeo P, Ruhland E, Roche C, Battini S, Cicek AE, Chenard MP, Hervieu V, Goichot B, Bachellier P, Walter T, Namer IJ.

Metabolites. 2019 Dec 11;9(12). pii: E300. doi: 10.3390/metabo9120300.

2.

Prognostic and predictive value of nuclear imaging in endocrine oncology.

Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A.

Endocrine. 2020 Jan;67(1):9-19. doi: 10.1007/s12020-019-02131-4. Epub 2019 Nov 16. Review.

PMID:
31734779
3.

PET/CMR: One More Step Toward Noninvasive Morphofunctional Diagnosis of Cardiac Malignancies.

El Ghannudi S, Germain P, Averous G, Gangi A, Schindler TH, Imperiale A.

JACC Cardiovasc Imaging. 2019 Oct 11. pii: S1936-878X(19)30853-8. doi: 10.1016/j.jcmg.2019.09.002. [Epub ahead of print] No abstract available.

PMID:
31607659
4.

Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient.

Rotania M, Chabrier G, Imperiale A.

Endocrine. 2019 Dec;66(3):691-692. doi: 10.1007/s12020-019-02074-w. Epub 2019 Sep 2. No abstract available.

PMID:
31478160
5.

Cardiac metastasis from medullary thyroid carcinoma: insights from multimodal molecular imaging and magnetic resonance imaging.

El Ghannudi S, Germain P, Schneegans O, Schindler TH, Imperiale A.

Eur Heart J Cardiovasc Imaging. 2020 Feb 1;21(2):231-232. doi: 10.1093/ehjci/jez132. No abstract available.

PMID:
31397474
6.

Limited role of carbidopa-assisted 18F-FDOPA PET/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms.

Imperiale A, Averous G, Helali M, Taieb D, Pessaux P, Goichot B, Addeo P, Bachellier P.

Ann Nucl Med. 2019 Sep;33(9):697-707. doi: 10.1007/s12149-019-01378-1. Epub 2019 Jun 15.

PMID:
31214959
7.

Cardiac Metastases of Small-Bowel CarcinoidAdded Value of 18F-Fluorodihydroxyphenylalanine Positron Emission Tomography Combined to Magnetic Resonance Imaging.

El Ghannudi S, Ben Abdelghani M, Germain P, Blondet C, Romain B, Imperiale A.

Circ Cardiovasc Imaging. 2019 Feb;12(2):e008405. doi: 10.1161/CIRCIMAGING.118.008405. No abstract available.

PMID:
30744393
8.

18F-FDOPA PET/CT Combined with MRI for Gross Tumor Volume Delineation in Patients with Skull Base Paraganglioma.

Helali M, Moreau M, Le Fèvre C, Heimburger C, Bund C, Goichot B, Veillon F, Hubelé F, Charpiot A, Noel G, Imperiale A.

Cancers (Basel). 2019 Jan 8;11(1). pii: E54. doi: 10.3390/cancers11010054.

9.

Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma.

Leroy-Freschini B, Amodru V, Addeo P, Sebag F, Vix M, Brunaud L, Klein M, Bahougne T, Bachellier P, Castinetti F, Goichot B, Chevalier E, Taieb D, Imperiale A.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):686-695. doi: 10.1007/s00259-018-4245-3. Epub 2019 Jan 7.

PMID:
30617961
10.

Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival.

Addeo P, d'Alessandro A, Averous G, Imperiale A, Faitot F, Goichot B, Bachellier P.

HPB (Oxford). 2019 Jun;21(6):653-661. doi: 10.1016/j.hpb.2018.10.010. Epub 2018 Dec 3.

PMID:
30522946
11.

Pancreatic Actinomycosis.

Addeo P, Dolfus C, Imperiale A, Faitot F, Averous G, Bachellier P.

J Gastrointest Surg. 2019 Feb;23(2):386-388. doi: 10.1007/s11605-018-3940-5. Epub 2018 Sep 5. No abstract available.

PMID:
30187330
12.

Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis.

Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):751-765. doi: 10.1007/s00259-018-4123-z. Epub 2018 Aug 9.

PMID:
30094461
13.

18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.

Heimburger C, Bund C, Addeo P, Goichot B, Imperiale A.

Clin Nucl Med. 2018 Sep;43(9):e324-e325. doi: 10.1097/RLU.0000000000002202.

PMID:
30052596
14.

Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.

Imperiale A, Latgé A, Schaff-Wendling F, Goichot B, Kurtz JE, Malouf GG.

Clin Nucl Med. 2018 Sep;43(9):701-702. doi: 10.1097/RLU.0000000000002231.

PMID:
30036245
15.

18F-FDOPA PET/CT of Nonfunctioning Paraganglioma of the Gastroepiploic Pedicle.

Leroy Freschini B, Addeo P, Averous G, Goichot B, Bachellier P, Imperiale A.

Clin Nucl Med. 2018 Sep;43(9):e326-e328. doi: 10.1097/RLU.0000000000002185.

PMID:
30004936
16.

Preoperative Imaging with 18F-FDOPA PET/CT for Small Bowel Neuroendocrine Tumors.

Addeo P, Bachellier P, Goichot B, Imperiale A.

J Gastrointest Surg. 2018 Nov;22(11):1992-1994. doi: 10.1007/s11605-018-3729-6. Epub 2018 Mar 12. No abstract available.

PMID:
29532361
17.

18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism.

Imperiale A, Taïeb D, Hindié E.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):654-657. doi: 10.1007/s00259-017-3920-0. No abstract available.

PMID:
29335763
18.

Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.

Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, Imperiale A, Baudin E, Lombes M.

Oncotarget. 2017 Jul 4;8(66):109924-109940. doi: 10.18632/oncotarget.18968. eCollection 2017 Dec 15.

19.

The Added Diagnostic Value of 18F-Fluorodihydroxyphenylalanine PET/CT in the Preoperative Work-Up of Small Bowel Neuroendocrine Tumors.

Addeo P, Poncet G, Goichot B, Leclerc L, Brigand C, Mutter D, Romain B, Namer IJ, Bachellier P, Imperiale A.

J Gastrointest Surg. 2018 Apr;22(4):722-730. doi: 10.1007/s11605-017-3645-1. Epub 2017 Dec 12.

PMID:
29235002
20.

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group.

Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.

PMID:
29107679

Supplemental Content

Loading ...
Support Center